10 天前 - … with signi cant mortality and morbidity. Dapagli ozin, an SGLT2 inhibitor shows
promising results in reducing cardiovascular events and improving clinical outcomes. However, …

11 天前 - … Significant reduction in CV death (29%), all-cause death (20%), and major adverse
cardiac events (18%) were also observed. However, it is not clear whether mortality was …

16 天前 - … failure exacerbation), as well as the risk of death from cardiovascular events [8, 9]. …
aims to assess the effect of dapagliflozin on functional capacity in patients with heart failure, …

17 天前 - … CV death and hHF were the clinical events of interest in this analysis. These outcomes
… The assumption that DPG had no effect on CV death or AE did not influence the results …

29 天前 - … Diabetic patients with concurrent CV or renal diseases face a greater risk of death
and CV events … Our study shown that dapagliflozin patients had a significant reduction in LV …

30 天前 - … Patients with diabetic neuropathy have a higher incidence of cardiovascular disease,
including heart failure (HF)… and clinical outcomes in patients with diabetes and established …

44 天前 - … related death are not different in the two groups. It is suggested that SGLT2 inhibitors
can reduce the risk of cardiovascular diseases but the current study did not identify any …

57 天前 - … death in patients with HF and reduced ejection fraction. The impact of dapagliflozin
in patients … We aimed to evaluate the efficacy and safety of dapagliflozin in patients with sRV. …

71 天前 - … ), current rates of adverse cardiovascular events remain high, … a wellestablished
therapy for chronic heart failure (HF) … empagliflozin and two utilized dapagliflozin. Median follow-…

89 天前 - … Effects of 6 months of dapagliflozin treatment on metabolic profile and endothelial
cell … type 2 diabetes mellitus patients without atherosclerotic cardiovascular disease. J Obes …